SEARCH

SEARCH BY CITATION

References

  • 1
    Khan KS, Wojdyla D, Say L, Gülmezoglu AM, Van Look PFA. WHO analysis of causes of maternal death: a systematic review. Lancet 2006;367:106674.
  • 2
    Ramanathan G, Arulkumaran S. Postpartum haemorrhage. J Obstet Gynaecol Can 2006;28:96773.
  • 3
    AbouZahr C. Global burden of maternal death and disability. Br Med Bull 2003;67:111.
  • 4
    United Nations. The millennium development goals report 2009 [Online]. 2009 [http://www.un.org/millenniumgoals/pdf/MDG%20Report%202009%20ENG.pdf]. Last accessed 26 July 2009.
  • 5
    National Institute of Population Studies (NIPS) [Pakistan], Macro International Inc. Pakistan Demographic and Health Survey 2006–07. Islamabad, Pakistan: National Institute of Population Studies and Macro International Inc., 2008.
  • 6
    Prendiville WJ, Harding JE, Elbourne DR, Stirrat GM. The Bristol third stage trial: active versus physiological management of third stage of labour. Br Med J 1988;297:1295300.
  • 7
    International Confederation of Midwives; International Federation of Gynaecologists and Obstetricians. Joint statement: management of the third stage of labour to prevent postpartum haemorrhage. J Midwifery Womens Health 2004;49:767.
  • 8
    WHO DoMPS. WHO Recommendations for the Prevention of Postpartum Haemorrhage. Geneva: World Health Organization, 2007.
  • 9
    Royal College of Obstetricians and Gynaecologists. Prevention and Management of Postpartum Haemorrhage. RCOG Green-top Guideline No. 52. London: Royal College of Obstetricians and Gynaecologists, 2009.
  • 10
    Gülmezoglu AM, Villar J, Ngoc NT, Piaggio G, Carroli G, Adetoro L, et al. WHO multicentre randomised study of misoprostol in the management of the third stage of labour. Lancet 2001;358:68995.
  • 11
    Gülmezoglu AM, Forna F, Villar J, Hofmeyr G. Prostaglandins for preventing postpartum haemorrhage. Cochrane Database Syst Rev 2007;3:CD000494.DOI: 10.1002/14651858.CD000494.pub3.
  • 12
    Alfirevic Z, Blum J, Walraven G, Weeks A, Winikoff B. Prevention of postpartum haemorrhage with misoprostol. Int J Gynecol Obstet 2007;99 (Suppl 2):198201.
  • 13
    Tsu VD, Shane B. New and underutilized technologies to reduce maternal mortality: call to action from a Bellagio workshop. Int J Gynecol Obstet 2004;85 (Suppl 1):8393.
  • 14
    Walraven G, Blum J, Dampha Y, Sowe M, Morison L, Winikoff B, et al. Misoprostol in the management of the third stage of labour in the home delivery setting in rural Gambia: a randomised controlled trial. Br J Obstet Gynaecol 2005;112:127783.
  • 15
    Høj L, Cardoso P, Nielsen BB, Hvidman L, Nielsen J, Aaby P. Effect of sublingual misoprostol on severe postpartum haemorrhage in a primary health centre in Guinea-Bissau: randomised double blind clinical trial. Br Med J 2005;331:7237.
  • 16
    Derman RJ, Kodkany BS, Goudar SS, Geller SE, Naik VA, Bellad MB, et al. Oral misoprostol in preventing postpartum haemorrhage in resource-poor communities: a randomised controlled trial. Lancet 2006;368:124853.
  • 17
    WHO. Unedited draft report of the 17th Expert committee on the selection and use of essential medicines, 23 to 27 March 2009. Unedited WHO technical report series (version 18 May 2009) [Online]. 2009 [www.who.int/selection_medicines/committees/expert/17/WEBuneditedTRS_2009.pdf]. Last accessed 8 July 2009.
  • 18
    WHO, Division of Family Health, Maternal Health and Safe Motherhood Programme. Care of Mother and Baby at the Health Centre: A Practical Guide. Geneva: World Health Organization, 1994.
  • 19
    Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 2001;134:66394.
  • 20
    Miller S, Tudor C, Thorsten V, Nyima, Kalyang, Sonam, et al. Randomized double masked trial of Zhi Byed 11, a Tibetan traditional medicine, versus misoprostol to prevent postpartum hemorrhage in Lhasa, Tibet. J Midwifery Womens Health 2009;54:13341.
  • 21
    Enakpene CA, Morhason-Bello IO, Enakpene EO, Arowojolu AO, Omigbodun AO. Oral misoprostol for the prevention of primary post-partum hemorrhage during third stage of labor. J Obstet Gynaecol Res 2007;33:8107.
  • 22
    Surbek DV, Fehr PM, Hösli I, Holzgreve W. Oral misoprostol for third stage of labor: a randomized placebo-controlled trial. Obstet Gynecol 1999;94:2558.
  • 23
    ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynaecologists number 76, October 2006: postpartum haemorrhage. Obstet Gynecol 2006;108:103947.
  • 24
    Cohen JH, Haas JD. Hemoglobin correction factors for estimating the prevalence of iron deficiency anemia in pregnant women residing at high altitudes in Bolivia. Rev Panam Salud Publica 1999;6:3929.
  • 25
    Patted SS, Goudar SS, Naik VA, Bellad MB, Edlavitch SA, Kodkany BS, et al. Side effects of oral misoprostol for the prevention of postpartum haemorrhage: results of a community-based randomised controlled trial in rural India. J Matern Fetal Neonatal Med 2009;22:248.
  • 26
    Ng PS, Chan ASM, Sin WK, Tang LCH, Cheung KB, Yuen PM. A multicentre randomised controlled trial of oral misoprostol and i.m. syntometrine in the management of the third stage of labor. Hum Reprod 2001;16:315.
  • 27
    Walraven G, Weeks A. The role of (traditional) birth attendants with midwifery skills in the reduction of maternal mortality. Trop Med Int Health 1999;4:5279.
  • 28
    Hofmeyr JG, Gülmezoglu AM. Misoprostol for the prevention and treatment of postpartum haemorrhage. Best Pract Res Clin Obstet Gynaecol 2008;22:102541.
  • 29
    Countdown Coverage Writing Group, Countdown to 2015 Core Group; Bryce J, Daelmans B, Dwivedi A, Fauveau V. Countdown to 2015 for maternal, newborn, and child survival: the 2008 report on tracking coverage of interventions. Lancet 2008;371:124758.